 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 GLOBE NEWSWIRE -- TLC Nasdaq: TLC, TWO: 4152, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization CDSCO of India has approved the New Drug Application NDA of Amphotericin B Liposome for Injection 50mg known as Ampholipad in Taiwan and AmphoTLCTM in India for immediate importation per approved usage and indication, to aid in the countrys emergency of acute liposomal amphotericin B shortage. 